Inga-Malin Simek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Inga-Malin Simek has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Joachim Widder
Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria
4 shared publications - Johannes Knoth
Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria
4 shared publications - Alina Sturdza
Comprehensive Cancer Center, Medical University of Vienna, General Hospital of Vienna, Austria
2 shared publications - Dietmar Georg
Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
2 shared publications - Gerd Heilemann
Department of Radiation Oncology Medical University of Vienna Vienna Austria
2 shared publications - Maximilian Schmid
Comprehensive Cancer Center, Medical University of Vienna, General Hospital of Vienna, Austria
2 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Springer Nature in Strahlentherapie und Onkologie
- p. 1-8
Thirty-Two Years of Radiotherapy for T1 Anal Cancer: Patterns, Outcomes, and Side-effects at a Single Institution
Purpose: Definitive chemoradiotherapy is the standard treatment for anal cancer, but the optimal management of small (T1) tumours remains unclear, as these tumours are underrepresented in prospective trials. Methods: We retrospectively analysed all patients with T1 anal carcinoma treated with curative intent at the Medical University of Vienna between 1990 and 2022. Patient, tumour, and treatment characteristics were extracted. Outcomes included overall survival (OS), disease-free survival (DFS), colostomy-free survival (CFS), and acute and late toxicity. Kaplan–Meier estimates, log-rank tests, and univariable Cox regression were used for exploratory time-to-event analyses. Results: Fifty-five patients (median age 67 years, range 31–86; female/male ratio 2.4:1) were included. The median prescribed dose was 58 Gy; 45% received concurrent chemotherapy and 35% a brachytherapy boost. Five-year OS, DFS, and CFS were 84.7%, 80.1%, and 85.3%, respectively. Late grade 3 toxicity occurred in six patients (11%), exclusively after 2D/3D radiotherapy. No statistically significant OS or DFS differences were demonstrated for brachytherapy, chemotherapy, nodal involvement, or IMRT/VMAT in exploratory univariable analyses. Conclusions: Patients with T1 anal carcinoma achieved favourable long-term tumour control and organ preservation after definitive radiotherapy or chemoradiotherapy. Severe late toxicity was observed only after 2D/3D radiotherapy; however, concurrent changes in treatment technique, dose, target volumes, and treatment era preclude attribution of this observation to any single treatment component. Numerically favourable outcomes with brachytherapy and concurrent chemotherapy were observed, but these findings remain hypothesis-generating and require validation in prospective studies.
- 24 September 2026
- Published by Springer Nature in Strahlentherapie und Onkologie
- p. 1-8
Open AccessThirty-Two Years of Radiotherapy for T1 Anal Cancer: Patterns, Outcomes, and Side-effects at a Single Institution
Purpose: Definitive chemoradiotherapy is the standard treatment for anal cancer, but the optimal management of small (T1) tumours remains unclear, as these tumours are underrepresented in prospective trials. Methods: We retrospectively analysed all patients with T1 anal carcinoma treated with curative intent at the Medical University of Vienna between 1990 and 2022. Patient, tumour, and treatment characteristics were extracted. Outcomes included overall survival (OS), disease-free survival (DFS), colostomy-free survival (CFS), and acute and late toxicity. Kaplan–Meier estimates, log-rank tests, and univariable Cox regression were used for exploratory time-to-event analyses. Results: Fifty-five patients (median age 67 years, range 31–86; female/male ratio 2.4:1) were included. The median prescribed dose was 58 Gy; 45% received concurrent chemotherapy and 35% a brachytherapy boost. Five-year OS, DFS, and CFS were 84.7%, 80.1%, and 85.3%, respectively. Late grade 3 toxicity occurred in six patients (11%), exclusively after 2D/3D radiotherapy. No statistically significant OS or DFS differences were demonstrated for brachytherapy, chemotherapy, nodal involvement, or IMRT/VMAT in exploratory univariable analyses. Conclusions: Patients with T1 anal carcinoma achieved favourable long-term tumour control and organ preservation after definitive radiotherapy or chemoradiotherapy. Severe late toxicity was observed only after 2D/3D radiotherapy; however, concurrent changes in treatment technique, dose, target volumes, and treatment era preclude attribution of this observation to any single treatment component. Numerically favourable outcomes with brachytherapy and concurrent chemotherapy were observed, but these findings remain hypothesis-generating and require validation in prospective studies.
- Open Access
- 25 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111306
Diffusion weighted imaging for gross tumor volume delineation in primary radiochemotherapy and image guided adaptive brachytherapy for cervical cancer
- 25 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111306
Open AccessDiffusion weighted imaging for gross tumor volume delineation in primary radiochemotherapy and image guided adaptive brachytherapy for cervical cancer
- Open Access
- 17 September 2024
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (1) , 71-81
Cardiac metastasis in uterine cervical cancer
Purpose: Cardiac metastasis from cervical cancer is rare and only scarcely documented. We aim to present a new case and systematically summarize the available literature. Materials and methods: PubMed, Scopus, Web of Science, Central, and ClinicalTrials.gov were systematically searched following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria. Results were screened via title, abstract, and full text. Additionally, the reference lists of all papers chosen for the review were screened. Results: Eighty-one papers were identified, describing 86 cases in total. Cardiac metastasis occurred at all stages of cervical cancer and in all age groups. Median time from initial diagnosis to diagnosis of cardiac metastasis was 12 months. Patients mainly complained of dyspnea and chest pain, 60.8% had pathologic ECG (electrocardiographic) findings. The cardiac mass was most frequently detected by transthoracic echography. The most common tumor histology was squamous cell carcinoma. Chemotherapy and surgical interventions were the main treatment modalities. Median survival after diagnosis of cardiac metastasis was 3 months. Conclusion: This largest review on cardiac metastases from cervical cancer confirmed the heart as a very infrequent site of metastasis. There are < 100 cases described in the literature, with very poor prognosis and undefined clinical management.
- 17 September 2024
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (1) , 71-81
Open AccessCardiac metastasis in uterine cervical cancer
Purpose: Cardiac metastasis from cervical cancer is rare and only scarcely documented. We aim to present a new case and systematically summarize the available literature. Materials and methods: PubMed, Scopus, Web of Science, Central, and ClinicalTrials.gov were systematically searched following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria. Results were screened via title, abstract, and full text. Additionally, the reference lists of all papers chosen for the review were screened. Results: Eighty-one papers were identified, describing 86 cases in total. Cardiac metastasis occurred at all stages of cervical cancer and in all age groups. Median time from initial diagnosis to diagnosis of cardiac metastasis was 12 months. Patients mainly complained of dyspnea and chest pain, 60.8% had pathologic ECG (electrocardiographic) findings. The cardiac mass was most frequently detected by transthoracic echography. The most common tumor histology was squamous cell carcinoma. Chemotherapy and surgical interventions were the main treatment modalities. Median survival after diagnosis of cardiac metastasis was 3 months. Conclusion: This largest review on cardiac metastases from cervical cancer confirmed the heart as a very infrequent site of metastasis. There are < 100 cases described in the literature, with very poor prognosis and undefined clinical management.
- Open Access
- 21 January 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 45, 100729
Metastases-directed local therapies (MDT) beyond genuine oligometastatic disease (OMD): Indications, endpoints and the role of imaging
- 21 January 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 45, 100729
Open AccessMetastases-directed local therapies (MDT) beyond genuine oligometastatic disease (OMD): Indications, endpoints and the role of imaging
- Open Access
- 29 December 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 45, 100715
Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort
- 29 December 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 45, 100715
Open AccessHealth-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort
- Open Access
- 17 November 2023
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 28, 100515
Clinical Implementation and Evaluation of Auto-Segmentation Tools for Multi-Site Contouring in Radiotherapy
- 17 November 2023
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 28, 100515
Open AccessClinical Implementation and Evaluation of Auto-Segmentation Tools for Multi-Site Contouring in Radiotherapy